Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases

Table 3 Adverse events in the two groups

Adverse events	All grades (%)			Grade 3-4 (%)
	TACE group (n = 22)	Control group (n = 38)	P value	TACE group (n = 22)	Control group (n = 38)	P value
Fever	20 (90.9)	5 (13.2)	0.0001	2 (9.1)	0 (0)	0.061
Fatigure	16 (72.7)	28 (73.7)	0.936	5 (22.7)	8 (21.1)	NA
Abnormal ALT	16 (72.7)	6 (15.8)	0.0001	5 (22.7)	0 (0)	0.005
Nausea	14 (63.6)	14 (36.8)	0.045	1 (4.5)	0 (0)	0.367
Ascites	5 (22.7)	10 (26.3)	0.757	0 (0)	0 (0)	NA
Diarhoea	4 (18.2)	5 (13.2)	0.712	0 (0)	0 (0)	NA
Hemorrhage	3 (8.3)	4 (10.5)	0.700	1 (4.5)	2 (5.3)	1.000
Neutropenia	12 (54.5)	16 (42.1)	0.352	3 (12.6)	3 (7.9)	0.659
Anemia	7 (31.8)	24 (63.2)	0.019	3 (12.6)	6 (15.8)	1.000
Thrombocytopenia	7 (31.8)	10 (26.3)	0.649	2 (10.5)	1 (2.6)	0.548

TACE: Transcatheter arterial chemoembolization; ALT: Alanine aminotransferase; NA: Not applicable.